Wolfe Research Downgrades Corcept Therapeutics to Underperform, Announces $50 Price Target

Wolfe Research analyst Kalpit Patel downgrades Corcept Therapeutics (NASDAQ:CORT) from Peer Perform to Underperform and announces $50 price target.